Free Trial
NASDAQ:APGE

Apogee Therapeutics (APGE) Stock Price, News & Analysis

$45.93
+3.74 (+8.86%)
(As of 07/11/2024 ET)
Today's Range
$42.87
$47.45
50-Day Range
$36.37
$54.31
52-Week Range
$14.19
$72.29
Volume
659,417 shs
Average Volume
559,380 shs
Market Capitalization
$2.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.00

Apogee Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
58.9% Upside
$73.00 Price Target
Short Interest
Bearish
21.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Apogee Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$784,312 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.64) to ($2.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.76 out of 5 stars

Medical Sector

611th out of 901 stocks

Biological Products, Except Diagnostic Industry

100th out of 150 stocks

APGE stock logo

About Apogee Therapeutics Stock (NASDAQ:APGE)

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

APGE Stock Price History

APGE Stock News Headlines

How did Wall Street get it so wrong?
CNBC's 'Prophet' who called dot-com crash issues controversial AI warning As AI stocks send the stock market to new highs every other month, the mainstream media is warning investors to prepare for another 2000-style tech crash. But the man CNBC nicknamed 'The Prophet' is going against the crowd. He accurately predicted the dot-com crash in 2000, and today, he has a controversial new warning about the AI craze. It could dictate your next decade of success – or failure – in the U.S. stock market.
Analyzing Apogee Therapeutics (APGE) and Its Rivals
How did Wall Street get it so wrong?
CNBC's 'Prophet' who called dot-com crash issues controversial AI warning As AI stocks send the stock market to new highs every other month, the mainstream media is warning investors to prepare for another 2000-style tech crash. But the man CNBC nicknamed 'The Prophet' is going against the crowd. He accurately predicted the dot-com crash in 2000, and today, he has a controversial new warning about the AI craze. It could dictate your next decade of success – or failure – in the U.S. stock market.
See More Headlines
Receive APGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/13/2024
Today
7/12/2024
Next Earnings (Estimated)
8/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:APGE
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$73.00
High Stock Price Target
$95.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+58.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-83,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.50 per share

Miscellaneous

Free Float
37,353,000
Market Cap
$2.69 billion
Optionable
Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Michael Thomas Henderson M.D. (Age 34)
    CEO & Director
    Comp: $1.17M
  • Ms. Jane Pritchett V. Henderson (Age 58)
    Chief Financial Officer
    Comp: $843.64k
  • Dr. Carl Linden Dambkowski M.D. (Age 38)
    Chief Medical Officer
    Comp: $870.83k
  • Ms. Noel Kurdi
    Vice President of Investor Relations
  • Mr. Matthew Batters J.D. (Age 48)
    Chief Legal Officer & Corporate Secretary
  • Ms. Emily Cox
    VP & Head of People
  • Dr. Rebecca Dabora Ph.D. (Age 64)
    Chief Development Officer
  • Ms. Wendy Aspden-Curran
    Senior Vice President of Clinical Operations
  • Dr. Drew Badger Ph.D.
    Senior VP and Head of Regulatory Affairs & Toxicology
  • Ms. Monica Forbes (Age 48)
    Senior Vice President of Finance

APGE Stock Analysis - Frequently Asked Questions

How have APGE shares performed this year?

Apogee Therapeutics' stock was trading at $27.94 at the beginning of the year. Since then, APGE shares have increased by 64.4% and is now trading at $45.93.
View the best growth stocks for 2024 here
.

How were Apogee Therapeutics' earnings last quarter?

Apogee Therapeutics, Inc. (NASDAQ:APGE) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.04.

When did Apogee Therapeutics IPO?

Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Friday, July 14th 2023. The company issued 17,650,000 shares at $15.00-$17.00 per share.

How do I buy shares of Apogee Therapeutics?

Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APGE) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners